Impax Laboratories has agreed to buy generic epinephrine drug and injectors maker Tower Holdings and three of its subsidiaries for $700 million in cash.

Advising Impax on the deal are Sullivan & Cromwell, Latham & Watkins and McDermott Will & Emery. Horsham, Pa.-based Tower has turned to Sidley Austin as its outside legal adviser. Sidley did not respond to inquiries about its deal team for Tower.